NIDO Surgical is a Boston-based medical device company specializing in innovative cardiac epicardial ablation solutions. They recently announced the acquisition of their groundbreaking epicardial ablation technology, SEPIA (Solution for Epicardial Ablation), by an undisclosed medical device company focused on electrophysiology. SEPIA enables electrophysiologists to administer a range of therapies directly to the epicardial surface of the heart, primarily targeting arrhythmias such as ventricular tachycardia (VT) and atrial fibrillation (AFib).

This advanced technology provides real-time visualization of the epicardial surface and enhances stability and control for complementary devices like ablation catheters. The acquisition aims to accelerate the development of SEPIA, ultimately improving the safety and effectiveness of epicardial procedures. This will potentially lead to reduced complications and lower rates of arrhythmias post-ablation.

NIDO's president and CEO, Thomas Marchand, emphasizes the strategic importance of this acquisition in the rapidly growing electrophysiology space, expressing optimism for the arrhythmia market. With the ability to directly visualize target areas and deliver therapy safely, SEPIA revolutionizes the treatment of life-threatening arrhythmias and offers innovative solutions for various heart diseases. NIDO Surgical has received substantial financial support, including grants from the National Institutes of Health and investments from private investors like Broadview Ventures.

Although the terms of the transaction remain undisclosed, the acquisition showcases the value and potential of SEPIA technology to provide essential tools for epicardial access. NIDO Surgical continues to push boundaries and contribute to advancements in cardiac care